2ⁿᵈ Edition of the Cancer R&D World Conference 2026
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 2ⁿᵈ Edition of the Cancer R&D World Conference 2026 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
2ⁿᵈ Edition of the Cancer R&D World Conference 2026
Event Overview
The 2ⁿᵈ Edition of the Cancer R&D World Conference 2026 (CRDWC 2026) is a premier global gathering organized by Precision Global Conferences. This hybrid event will take place from September 21 to 23, 2026, at the Hilton Garden Inn Miami Dolphin Mall, FL, USA. It aims to accelerate cancer research and development by fostering collaborations among researchers, scholars, industry leaders, and medical professionals.
Themed around advancing precision oncology, the conference will feature cutting-edge research in areas such as CAR-T cell therapy, cancer genomics, immuno-oncology, and emerging biomarkers. Attendees can participate either in-person in Miami or virtually, ensuring global accessibility.
Key Details
- Dates: September 21–23, 2026
- Venue: Hilton Garden Inn Miami Dolphin Mall, FL, USA
- Event Type: Hybrid (In-person & Virtual)
- Organizer: Precision Global Conferences
- Contact: +1-571-5561014 | cancer@precisionglobalconferences.com
- Accreditation: 100+ visitors expected
About the Conference
CRDWC 2026 provides a dynamic platform for professionals in oncology and cancer research to share innovative discoveries, engage in expert-led sessions, and network with global peers. The event emphasizes translational research, therapeutic advancements, and interdisciplinary collaborations to address challenges in cancer diagnosis, treatment, and prevention.
The conference will include scientific sessions, workshops, and exhibitions showcasing breakthroughs in:
- Oncology research and therapeutic targets
- Immuno-oncology and cell-based therapies
- CAR-T cell therapy and next-gen gene therapies
- Cancer prevention and early detection strategies
- Emerging biomarkers and personalized medicine
Who Attends
The conference attracts a diverse audience of stakeholders in cancer research and development, including:
- Academic researchers and faculty members
- Medical oncologists and healthcare professionals
- Pharmaceutical and biotech industry representatives
- Students and postdoctoral scholars
- Government and nonprofit organization delegates
- Investors and venture capital firms in healthcare innovation
Location & Audience Reach
Venue: Hilton Garden Inn Miami Dolphin Mall, FL, USA. Miami’s strategic location offers excellent connectivity for international attendees.
Audience Reach: Global, with a focus on North America, Europe, and Asia-Pacific regions. The hybrid format ensures participation from researchers and industry leaders worldwide.
Sample Buyer Profiles
| Priority | Company | Website | Best Title to Target | Why a Good Fit |
|---|---|---|---|---|
| 1 | Roche Holding Ltd. | roche.com | Oncology Research Director | Global leader in oncology R&D with focus on personalized medicine. |
| 2 | Novartis International AG | novartis.com | Cell & Gene Therapy Manager | Active in CAR-T and gene therapy development. |
| 3 | Foundation Medicine, Inc. | foundationmedicine.com | Director of Biomarker Research | Specializes in genomic profiling and diagnostic solutions. |
| 4 | Memorial Sloan Kettering Cancer Center | mskcc.org | Clinical Research Oncologist | Pioneering work in immuno-oncology and clinical trials. |
| 5 | Bluebird Bio | bluebirdbio.com | Gene Therapy Development Lead | Focus on gene therapies for blood cancers and beyond. |
Target Job Profiles & Industries
Key Industries:
- Biotechnology
- Pharmaceuticals
- Medical Research
- Healthcare Technology
- Academic Research Institutions
- Nonprofit Organizations
Target Job Titles:
- Oncology Research Scientist
- Cell & Gene Therapy Specialist
- Director of Clinical Research
- Biomarker Development Manager
- Medical Affairs Director
- Business Development Manager (Healthcare Sector)
Estimated Attendance & Key Focus Areas
Expected Footfall: Over 100 attendees, including researchers, clinicians, industry leaders, and investors. The hybrid format may expand virtual participation.
Key Focus Areas:
- Advances in immuno-oncology and CAR-T cell therapy
- Genomic-driven cancer diagnostics and treatment
- Translational research bridging lab and clinic
- Global collaboration for cancer prevention
- Emerging technologies in drug discovery
Buyer Engagement & Contact
For tailored attendee list requests, please share your client’s website to align with their product focus. For example:
- If your client specializes in biomarker diagnostics, we’ll prioritize companies like Foundation Medicine or Guardant Health.
- For cell therapy platforms, we’ll highlight prospects like CRISPR Therapeutics or Kymab.
Contact Us:
Email: cancer@precisionglobalconferences.com
Phone: +1-571-5561014
Data sheet
2nd Edition of the Cancer R&D World Conference 2026 – Event Attendee & Buyer Profile Analysis
Event date: September 21–23, 2026
Location: Hilton Garden Inn Miami Dolphin Mall, Miami, Florida, USA
Event status: Upcoming
Research date: June 30, 2026
Event Overview
| Event Name | 2nd Edition of the Cancer R&D World Conference 2026 (CRDWC 2026) |
| Event Date | September 21–23, 2026 |
| Event Status | Upcoming |
| Venue | Hilton Garden Inn Miami Dolphin Mall |
| City | Miami |
| State / Region | Florida |
| Country | USA |
| Organizer | Precision Global Conferences |
| Official Event Website | cancerglobalconference.com |
| Event Type | Hybrid conference and R&D summit (in-person and virtual) |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research |
| Audience Reach | Global |
| Estimated Attendance / Expected Footfall | 100+ visitors |
| Attendance Data Reliability | Confirmed organizer claim on the official event website |
| Main Purpose of Event | To convene oncology researchers, clinicians, academic institutions, biotech and pharma stakeholders, and related innovation partners around cancer R&D, precision oncology, immuno-oncology, biomarkers, cell and gene therapy, and translational collaboration. |
About the Event
The 2nd Edition of the Cancer R&D World Conference 2026 is a hybrid oncology research conference organized by Precision Global Conferences and scheduled for September 21–23, 2026 in Miami, Florida, USA. Based on the official event description, the conference is positioned around cancer research and development, with session themes including oncology research, therapeutic targets, biomarkers, prevention, immuno-oncology, cancer vaccines, CAR-T cell therapy, and next-generation cell and gene therapies.
From a commercial and partnership perspective, this event matters because it brings together the scientific, clinical, translational, and innovation sides of oncology. The audience is likely to include academic cancer centers, hospital-based researchers, biotech and pharmaceutical R&D teams, laboratory leaders, diagnostics stakeholders, and collaboration-focused business development professionals. It is more suitable for targeted B2B lead building within oncology and life sciences than for broad-volume attendee list acquisition, given the organizer-reported scale of 100+ visitors.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Academic oncology researchers | Universities, cancer biology departments, medical schools | Influence research tools, collaborations, grant-linked purchasing, and platform adoption | High relevance for lab technology, assay providers, software, biomarkers, and translational research services |
| Cancer center and hospital research leaders | Cancer institutes, university hospitals, clinical research programs | Evaluate diagnostics, clinical platforms, therapeutic partnerships, and trial infrastructure | High relevance for clinical technology, genomics, data systems, tissue analysis, and translational service providers |
| Biotech and pharmaceutical R&D teams | Oncology drug developers, immunotherapy and cell/gene therapy firms | Direct or strong influence over outsourcing, platform selection, partnership scouting, and scientific evaluation | Very high relevance for CROs, CDMOs, biomarkers, companion diagnostics, preclinical tools, and AI-enabled R&D vendors |
| Immuno-oncology and cell therapy specialists | CAR-T, cell therapy, immunotherapy, and gene therapy programs | Drive technical evaluation and pilot engagement | High relevance for manufacturing support, analytics, process development, and translational clinical partners |
| Biomarker and diagnostics developers | Molecular diagnostics labs, assay developers, precision medicine groups | Assess testing workflows, data tools, sample handling, and commercialization partnerships | High relevance for lab equipment, sequencing, bioinformatics, specimen logistics, and assay support vendors |
| Clinical investigators and translational medicine teams | Clinical trial units, translational oncology departments | Influence study design support, recruitment technology, data capture, and therapeutic collaboration | Relevant for eClinical, patient engagement, biospecimen, and research data vendors |
| Scientific committee and KOLs | Recognized professors, institute chairs, senior investigators | High influence over peer adoption, collaborations, and vendor credibility | Important for partnership development, speaker-led brand visibility, and scientific validation |
| Business development and alliance teams | Biotech, pharma, CRO, diagnostics, and research platform companies | Direct responsibility for licensing, collaboration, channel, and service partner discussions | High-value for outbound meetings and targeted B2B networking |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Miami | Local medical, university, clinical, and healthcare innovation participants | Medium | Host city supports in-person attendance and business meetings for South Florida stakeholders |
| Florida | Regional hospitals, medical schools, biotech firms, and oncology programs | Medium to High | Florida location increases accessibility for regional clinical and academic institutions |
| US national market | Researchers, cancer centers, and biotech/pharma teams from major US hubs | High | Official site positions the conference for delegates across the globe, with several US-based committee organizations listed |
| International academic and research markets | Europe, Asia, Middle East, and Africa-based universities and research groups | High | Confirmed featured speakers and committee affiliations span multiple countries; hybrid access expands international participation |
| Virtual attendance layer | Remote researchers, clinicians, and life sciences professionals unable to travel | Medium to High | Organizer explicitly offers virtual participation, improving geographic reach beyond physical venue limits |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The event is branded as a world conference, supports virtual participation, and lists committee/speaker organizations from the USA, Europe, Asia, and Africa. Physical scale is modest, but geographic reach is international. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| University of Texas MD Anderson Cancer Center | Cancer center / academic medical institution | Committee-linked institution with direct relevance to oncology research, translational science, and technology evaluation | mdanderson.org | Chair of Cancer Biology, Director Translational Research, Procurement Manager, Lab Operations Director | Confirmed Speaker Organization |
| Dana-Farber Cancer Institute | Cancer institute | Committee-linked institution highly relevant for oncology R&D, precision medicine, and clinical research purchasing | dana-farber.org | Principal Investigator, Clinical Research Director, Strategic Sourcing Manager, Molecular Diagnostics Leader | Confirmed Speaker Organization |
| Rutgers Robert Wood Johnson Medical School | Medical school / academic research institution | Committee-linked institution relevant for pathology, laboratory medicine, and translational partnerships | rwjms.rutgers.edu | Professor Pathology, Lab Director, Research Administration Director, Procurement Specialist | Confirmed Speaker Organization |
| Hebei University of Technology | University research institution | Committee-linked university with scientific relevance and possible collaboration interest in applied research tools | hebut.edu.cn | Professor, Research Director, International Collaboration Director, Lab Procurement Lead | Confirmed Speaker Organization |
| Carol Davila University of Medicine and Pharmacy | Medical university | Featured speaker affiliation with clear relevance to oncology and medical research networking | umfcd.ro | Professor Oncology, Department Head, Research Programs Manager, Clinical Trials Lead | Confirmed Speaker Organization |
| Medancer Initiative Rwanda | Healthcare / nonprofit cancer initiative | Featured speaker organization relevant for oncology awareness, care models, and partnership development | medancerinitiative.org | Program Director, Partnerships Director, Clinical Outreach Lead, Operations Manager | Confirmed Speaker Organization |
| Shaanxi University of Chinese Medicine | University / medical research institution | Featured speaker affiliation; relevant for research collaboration and scientific exchange | sntcm.edu.cn | Professor, Translational Research Lead, International Programs Director, Laboratory Manager | Confirmed Speaker Organization |
| Enjoy Rehab PT PC | Healthcare practice | Featured speaker affiliation; more peripheral to oncology R&D but relevant for supportive care and rehabilitation topics | Public website not clearly verified from official event text | Clinical Director, Practice Owner, Rehabilitation Lead | Confirmed Speaker Organization |
| Ahmed Ben Bella Oran 1 University | University research institution | Featured speaker affiliation relevant for international scientific collaboration and research procurement influence | univ-oran1.dz | Professor, Research Director, Department Head, Grants and Procurement Coordinator | Confirmed Speaker Organization |
| Jamia Hamdard University | University / health sciences institution | Featured speaker affiliation relevant for cancer-related research and pharmaceutical collaboration | jamiahamdard.edu | Professor, Dean Research, Oncology Research Lead, Sourcing Manager | Confirmed Speaker Organization |
| Sichuan University | University research institution | Two featured speakers are listed from this university, indicating notable current-year representation | scu.edu.cn | Professor, Principal Investigator, Research Institute Director, Lab Procurement Lead | Confirmed Speaker Organization |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Scientific Officer | R&D | C-Level | Owns scientific direction, platform evaluation, and external research partnerships. |
| 2 | VP / Head of Oncology R&D | R&D | VP | Key buyer/influencer for oncology platforms, outsourcing, and translational collaboration. |
| 3 | Director of Translational Medicine | Clinical / Translational Research | Director | Bridges discovery science and clinical application; high relevance for biomarkers and diagnostics. |
| 4 | Principal Investigator / Professor of Oncology | Academic Research | Senior | Influences lab adoption, collaboration, and sponsored research engagement. |
| 5 | Director of Clinical Research | Clinical Research | Director | Relevant for trial-enabling technology, patient data tools, and study support vendors. |
| 6 | Head of Immuno-Oncology | R&D | Director / VP | Directly relevant to core conference tracks including immuno-oncology and cell therapies. |
| 7 | Director of Biomarker Research | Diagnostics / Research | Director | Evaluates assay platforms, sequencing workflows, and analytical technologies. |
| 8 | Laboratory Director | Laboratory Operations | Director | Core buyer for instrumentation, workflow software, and testing support services. |
| 9 | Strategic Sourcing Manager | Procurement | Manager | Formal procurement contact for research tools, reagents, software, and outsourced services. |
| 10 | Business Development Director | Business Development / Alliances | Director | Important for licensing, partnerships, distributor relationships, and collaboration deals. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Biotechnology | Strong fit for cancer therapeutics, biomarker innovation, and translational science | Partnership outreach, research services, and platform adoption |
| 2 | Pharmaceuticals | Relevant to oncology drug development and precision medicine programs | R&D outsourcing, diagnostics, and alliance-building |
| 3 | Hospital & Health Care | Cancer centers and hospital research units are core audience segments | Clinical technology and translational program targeting |
| 4 | Research | Covers institutes and organizations centered on scientific discovery | Research collaboration and tool sales |
| 5 | Higher Education | Universities and medical schools are visibly represented in the speaker roster | Academic outreach, lab equipment, and sponsored research |
| 6 | Medical Devices | Relevant for diagnostics, lab systems, and oncology-supporting technologies | Clinical and lab workflow sales |
| 7 | Information Technology & Services | Supports bioinformatics, research data, AI-enabled discovery, and clinical informatics | Data platform and analytics targeting |
| 8 | Computer Software | Useful for oncology analytics, LIMS, trial software, and precision medicine tools | Software prospecting into research and clinical teams |
| 9 | Health, Wellness & Fitness | Secondary fit for supportive care, rehabilitation, and patient-centered services | Supportive oncology partnerships |
| 10 | Nonprofit Organization Management | Relevant for cancer initiatives, foundations, and awareness organizations | Program partnerships and sponsorship outreach |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | 100+ visitors | Confirmed | Official event website accreditation/visitor count display | Organizer-stated figure; exact final attendance not yet available |
| Exhibitor count | Not publicly confirmed | Unconfirmed | Official site references sponsors/exhibitors but does not provide a count in the supplied content | Do not assume exhibitor volume |
| Buyer count | Attendance figure not publicly confirmed by the organizer | Unconfirmed | No buyer-only count published in supplied official text | Audience appears mixed across researchers, delegates, students, scholars, and industry participants |
| Speaker count | At least 8 featured speakers shown in supplied official text | Confirmed partial list | Featured speakers section on official website | This is not necessarily the full speaker roster |
| Scientific committee count | At least 4 committee members shown in supplied official text | Confirmed partial list | Committee section on official website | Likely more listed on the full website |
| Sponsor count | Not publicly confirmed | Unconfirmed | Official site includes sponsor section without clear numeric count in supplied text | Avoid using unsupported sponsor totals |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Precision oncology | Better patient stratification, data interpretation, and targeted therapy support | Demonstrate clinical utility, biomarker alignment, and research workflow fit | Precision medicine software, companion diagnostics, molecular profiling tools |
| Cancer genomics | Sequencing efficiency, data analysis, and translational interpretation | Engage genomic lab directors and translational research leaders | NGS solutions, bioinformatics, data storage, interpretation platforms |
| Immuno-oncology | Novel therapeutic targets, immune response analysis, preclinical support | Target therapy developers and translational teams | Assay platforms, CRO services, immune profiling, translational analytics |
| CAR-T cell therapy | Manufacturing scalability, quality analytics, and clinical progress support | High-value discussions with cell therapy leads and biotech R&D heads | Cell processing tools, QC systems, CDMO support, trial operations services |
| Biomarkers | Detection accuracy, prognostic validation, and assay reproducibility | Target biomarker directors and pathology/lab teams | Assays, sample management, laboratory systems, validation services |
| Cancer prevention and early detection | Screening models, risk tools, and prevention program support | Engage public health, diagnostics, and clinical research stakeholders | Screening technologies, risk analytics, education and outreach platforms |
| Next-generation cell and gene therapies | Process development, regulatory support, and translational readiness | Strong partnership-led outreach angle | Manufacturing support, analytics, research reagents, platform technologies |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | High | Audience is niche but strongly aligned to oncology R&D, research tools, diagnostics, and partnerships. |
| Decision-maker availability | Medium to High | Scientific and clinical leaders are likely present, though many attendees may be researchers rather than procurement-only buyers. |
| Data collection potential | Medium | Official website confirms speakers and committee organizations, but broad attendee directory visibility is not publicly confirmed. |
| Apollo targeting potential | Very High | Clear industry, title, and departmental segmentation exists across biotech, pharma, hospitals, and academia. |
| Geographic targeting potential | High | Hybrid format supports both US-based and international prospecting around oncology research clusters. |
| Best outreach approach | High | Use thought-leadership and collaboration-led outreach rather than generic sales messaging. |
| Overall lead quality | High | Best suited for targeted oncology/life-sciences outreach with higher-value accounts rather than mass-scale volume. |
| Best use case | High | KOL mapping, research institution targeting, biotech/pharma outreach, partnership development, and speaker-organization prospecting. |
| Limitations / risks | Medium | Organizer-reported size is 100+ visitors; limited scale may reduce list volume. Current-year attendee list is not publicly confirmed. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Biotechnology; Pharmaceuticals; Hospital & Health Care; Research; Higher Education; Medical Devices; Information Technology & Services; Computer Software | Focus on oncology R&D buyers, scientific users, and translational collaborators |
| Departments | Research, Clinical Research, Medical Affairs, Laboratory Operations, Procurement, Business Development, Partnerships, Innovation | Align outreach to both scientific and commercial decision-makers |
| Seniority | C-Level, VP, Director, Head, Manager, Owner (for specialist practices or smaller biotech firms) | Prioritize budget holders and high-influence evaluators |
| Job titles | Chief Scientific Officer; VP Oncology R&D; Head of Translational Medicine; Director Clinical Research; Director Biomarkers; Head of Immuno-Oncology; Principal Investigator; Laboratory Director; Strategic Sourcing Manager; Business Development Director | Build targeted contact lists around actual conference themes |
| Geography | United States; Florida; Miami; major US oncology hubs; Europe; India; China; Middle East; Africa | Reflects hybrid/global reach and visible speaker geographies |
| Employee size | 11–50; 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Covers emerging biotech firms through large academic and hospital systems |
| Keywords | oncology, cancer research, immuno-oncology, CAR-T, cell therapy, gene therapy, biomarkers, cancer genomics, translational medicine, precision oncology | Improves relevance when industry classification alone is broad |
| Technologies | Use only if relevant to client offering: sequencing platforms, LIMS, bioinformatics, clinical trial software, cloud analytics | Useful for software, data, and laboratory technology suppliers |
| Revenue range | Not mandatory; test mid-market to enterprise for pharma/hospital systems and all sizes for research institutions | Prevents over-filtering in academic and nonprofit segments |
| Company type | Public companies, private companies, nonprofits, universities, hospitals, research institutes | Captures the mixed institution profile typical of oncology conferences |
Suggested Apollo Search Logic: ("oncology" OR "cancer research" OR "precision oncology" OR "immuno-oncology" OR "CAR-T" OR "cell therapy" OR "gene therapy" OR biomarker* OR genomics OR "translational medicine") AND (Director OR Head OR VP OR "Chief Scientific Officer" OR "Principal Investigator" OR "Laboratory Director" OR "Strategic Sourcing Manager" OR "Business Development Director").
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| Cancer R&D World Conference official website | Official event website | Event title, dates, venue, city, country, hybrid format, organizer contact, visitor claim, scientific sessions, committee and featured speaker organizations | High |
| Hilton Garden Inn Miami Dolphin Mall | Venue website | Venue identity and Miami location naming convention | High |
| Official website supplied text snapshot | Primary-source content provided by user | Used as the primary source of truth per instruction; no contradictory claims introduced | High |
Verification note: This event appears suitable for focused B2B attendee and buyer profiling in oncology, research, and life sciences. Current-year public attendee lists are not visible in the supplied official content, so this report relies on confirmed event facts plus confirmed committee and speaker organization evidence rather than unsupported attendee assumptions.
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 2ⁿᵈ Edition of the Cancer R&D World Conference 2026 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds